Divi's Laboratories (DIVISLAB.NS) Stock Price
Divi's Laboratories Price
Over the last 19 years Divi's Laboratories grew revenue by 18.4% annually, reaching 93.60 B INR. Earnings per share have grown at 19.8% per year over the last 19 years. For Divi's Laboratories, the net margin of 23.4% is down versus 28.5% a few years ago. At today's price the dividend yield works out to roughly 0.31%. The payout ratio is around 36% of earnings. The dividend has grown at 24.0% per year over the past 19 years. The consensus 12-month price target for Divi's Laboratories is 7,012.50 INR, about 26.7% below where the stock trades today. Of 36 analysts, 20 rate the stock a buy — an overall Buy consensus. The stock trades about 68% above its 52-week low.
Divi's Laboratories stock price
Divi's Laboratories business model & stock analysis
Frequently asked questions about Divi's Laboratories
The business model of Divi's Laboratories Ltd revolves around the manufacture and supply of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies worldwide. With a focus on quality, innovation, and cost-effective production, Divi's Labs caters to a wide range of therapeutic segments including generics, custom synthesis, and development of new molecules. By leveraging its strong research and development capabilities, cutting-edge technology, and state-of-the-art manufacturing facilities, Divi's Labs has established itself as a trusted supplier in the global pharmaceutical industry.
Divi's Laboratories Ltd is primarily active in the pharmaceutical industry.
The main competitors of Divi's Laboratories Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Cipla Ltd.
Divi's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1990. It is headquartered in Hyderabad, Telangana. The company specializes in the research, development, and manufacturing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Divi's Laboratories has a strong focus on quality with a global customer base and is recognized for its state-of-the-art manufacturing facilities. Over the years, the company has consistently grown and expanded its product portfolio. Divi's Laboratories is committed to innovation, research, and delivering high-quality healthcare solutions to meet the needs of patients worldwide.
Divi's Laboratories Ltd has achieved numerous significant milestones throughout its journey. Notably, the company has consistently demonstrated excellence in the pharmaceutical sector since its establishment. Divi's Laboratories Ltd has successfully garnered a strong reputation for its high-quality manufacturing practices and commitment to innovation. The company has also gained several certifications, including ISO 9001, ISO 14001, and OHSAS 18001, further solidifying its credibility. Moreover, Divi's Laboratories Ltd has expanded its operations globally, establishing a strong presence in various international markets. These incredible achievements highlight Divi's Laboratories Ltd's unwavering dedication to delivering exceptional pharmaceutical solutions while maintaining the highest standards of quality and compliance.
Divi's Laboratories Ltd is primarily present in India, with its headquarters located in Hyderabad. The company operates multiple manufacturing facilities in different locations across India, including Visakhapatnam, Hyderabad, and Mahad. Divi's Laboratories Ltd focuses on manufacturing and supplying active pharmaceutical ingredients (APIs) and intermediates globally. It has a strong presence in various countries and regions, including the United States, Europe, Japan, Korea, and several emerging markets. With its commitment to quality and adherence to international regulatory standards, Divi's Laboratories Ltd has established itself as a trusted supplier of pharmaceutical products worldwide.
Divi's Laboratories Ltd is committed to upholding values of excellence, integrity, and innovation. With a strong corporate philosophy centered around quality and customer satisfaction, the company continually strives to provide top-notch pharmaceutical products and services. Divi's Laboratories Ltd focuses on research and development to ensure cutting-edge solutions and advancements in the field. The company's emphasis on ethical practices and transparency reflects its commitment to maintaining strong relationships with stakeholders. Divi's Laboratories Ltd's dedication to continuous improvement and market leadership makes it a preferred choice for investors seeking a reliable and progressive pharmaceutical company.
Analysts currently set an average price target of 6,987.18 INR for the Divi's Laboratories stock (median: 7,012.50 INR), implying -27.4 % versus the latest price. The consensus is based on 36 analyst ratings.
36 analysts currently rate the Divi's Laboratories stock: 21 recommend buying, 6 holding and 9 selling. For 2026, analysts expect Divi's Laboratories to generate revenue of 106.46 B INR and earnings per share of 115.11 INR.
Converted at the current exchange rate, the Divi's Laboratories share trades at 87.62 EUR (9,567.00 INR).
The Divi's Laboratories share (DIVISLAB.NS) is listed on 2 stock exchanges, including: NSE (Indien) (DIVISLAB.NS).
Divi's Laboratories Ltd is an Indian company that manufactures pharmaceutical active ingredients and intermediates for the global market. The company was founded in 1990 and is headquartered in Hyderabad, India. Divi's Laboratories' business model is based on extensive research and development and high production capacity. The company follows a vertically integrated production strategy, engaging in the development of new active ingredients and the production of intermediates and finished products. Divi's Laboratories serves a variety of industries such as the pharmaceutical and cosmetic industries, agriculture, and the food industry. The company offers a wide range of products such as antibiotics, antidepressants, vitamins, and folic acid for the pharmaceutical industry. For the cosmetic and food industries, the company offers emulsifiers, fragrances and flavors, as well as dyes and sunscreens. The company has two modern manufacturing facilities with a total capacity of over 500 tons per year. Divi's Laboratories continuously invests in state-of-the-art production facilities to increase capacity and productivity. Divi's Laboratories specializes in the manufacture of pharmaceutical active ingredients and intermediates and therefore enjoys a good reputation in the industry. The company has established a strong position in the market in recent years and has expanded into various countries such as the USA, Europe, and Asia. The company is also successful in research and development of new products. Divi's Laboratories has its own research and development department that develops new synthetic methods and processes for the production of active ingredients. The company works closely with customers to produce customized products for their specific requirements. Furthermore, Divi's Laboratories is involved in the research of natural substances that can be used in the medical field. The company has its own department for biotechnological research and development to isolate new natural substances and investigate their potential for medical application. In summary, Divi's Laboratories' business model is very successful and focused on a wide range of products and extensive research and development. The company has established a strong position in the global market for pharmaceutical active ingredients and intermediates and is on track to further expand its position.
The expected revenue of Divi's Laboratories is 106.46 B INR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Divi's Laboratories is 30.53 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Divi's Laboratories is currently 83.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Divi's Laboratories stock.
The price-to-sales ratio (P/S) of Divi's Laboratories is currently 23.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Divi's Laboratories stock.
The Eulerpool Quality Score for Divi's Laboratories is 6/10.
The ISIN of Divi's Laboratories is INE361B01024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Divi's Laboratories is DIVISLAB.NS. The ticker symbol is used to trade Divi's Laboratories shares on the stock exchange.
Over the past 12 months, Divi's Laboratories paid a dividend of 30.00 INR . This corresponds to a dividend yield of about 0.31 %. For the coming 12 months, Divi's Laboratories is expected to pay a dividend of 30.00 INR.
The current dividend yield of Divi's Laboratories is 0.31 %.
Divi's Laboratories pays a dividend, distributed in the months of August, July.
Divi's Laboratories paid dividends every year for the past 23 years.
For the upcoming 12 months, dividends amounting to 30.00 INR are expected. This corresponds to a dividend yield of 0.31 %.
Divi's Laboratories is assigned to the 'Health' sector.
In the year 2025, Divi's Laboratories distributed 30 INR as dividends.
The dividends of Divi's Laboratories are distributed in INR.
Divi's Laboratories stock
Divi's Laboratories Peer Group
Divi's Laboratories Ticker
Divi's Laboratories FIGI
All fundamentals and in-depth analysis of Divi's Laboratories
Our stock analysis for Divi's Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Divi's Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.